We push the boundaries of molecular diagnostics through quantitative technologies.
BillionToOne is a precision diagnostics company with the mission to make molecular diagnostics more accurate, efficient, and accessible for all. Our patent-pending QCT molecular counter platform is the only technology platform that can accurately count the DNA molecules to the single-count level.
BillionToOne to present series of single-gene NIPT posters at 2020 ACMG Annual Clinical Genetics Meeting
FEB 26, 2020
BillionToOne to present single-gene NIPT poster at Society of 40th Maternal Fetal Medicine (SMFM) Conference
JAN 03, 2020
QCT Molecular Counting Platform
Our QCT (Quantitative Counting Templates) molecular counter technology uses specifically designed molecular standards that encode the molecular count information in sequencing data in a way that can be decoded using machine learning algorithms (4 US/PCT patents pending). This allows us to get extremely quantitative molecular counting information from any sequencing technology.
- Tsao et al., 2019 “A novel high-throughput molecular counting method with single base-pair resolution enables accurate single-gene NIPT” [Preprint]
- Itzap et al., 2018 “A Novel Next-Generation Sequencing Based Assay for Non-invasive Prenatal Testing of Sickle Cell Disease Without Paternal DNA” Poster session presented at the 60th American Society of Hematology Annual Meeting, Orlando, FL
Collaborate With Us
BillionToOne Inc. is conducting multiple studies on the clinical utility and clinical validity of the single-gene NIPT test. If you are interested in collaboration, email us at firstname.lastname@example.org